Primary Liver Cancer
Conditions
Interventions
Non-HCC group:None
Sponsors
Meishan City Peoples Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Signed informed consent prior to the trial and able to complete the study as required by the trial protocol. 2.Age 18~75 years old (including boundary value); 3.HBsAg positive for more than 6 months; 4.ALT, AST<=1×ULN (3 or more consecutive follow-ups, at least 3 months apart); 5.The diagnostic criteria for HCC refer to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition), and refer to the following diagnostic roadmap for details;
Exclusion criteria
Exclusion criteria: 1.Patients treated with warfarin or vitamin K within the last 3 months; 2.Patients with HCC who have been treated with surgical resection, radiofrequency ablation, radiotherapy, or chemotherapy. 3.Have clinically significant acute and chronic liver disease not due to HBV infection (fatty liver disease is excluded at the discretion of the investigator); 4.Combined with serious diseases of the circulatory, respiratory, urinary, blood, metabolic, immune, psychiatric, nervous, renal and other systems. 5.Those who have had major trauma or major surgery within 3 months before screening; or those who plan to undergo surgery during the study; 6.Donated or lost >= 400 mL of blood within 3 months prior to screening, or received a blood transfusion; or blood donation or blood loss = 200 mL within 1 month prior to screening. 7.People with severe mental illness or cognitive impairment. 8.Pregnant or lactating patients, or patients preparing to become pregnant; 9.Those who have participated in other clinical trials or are participating in other clinical trials in the last 3 months. 10.According to the judgment of the doctor, the probability of inclusion is low (including inability to understand the project requirements, poor compliance, frailty, inability to ensure that the protocol can be implemented as required, etc.), or the doctor believes that there are other factors that are not suitable for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alpha-fetoprotein;Des-gamma-carboxy prothrombin; | — |
Countries
China
Contacts
Public ContactZiqiao Yang
Meishan City Peoples Hospital
Outcome results
None listed